Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Congress Scientific Watch

The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings (in partnership with medwireNews).

Login and start reading, or Join ESMO

Filter by:

112 results

Hepatobiliary Cancers;  Personalised/Precision Medicine;  Radiation Oncology;  Therapy

SBRT Boosts Overall Survival For Sorafenib-Treated Locally Advanced HCC Patients

From 2023 ASCO GI Cancers Symposium:
Adding stereotactic body radiation therapy to sorafenib significantly improves survival outcomes for patients with locally advanced hepatocellular carcinoma unsuitable for surgery, ablation or transarterial embolisation

Gastric Cancer;  Personalised/Precision Medicine

INTEGRATE IIa Supports Regorafenib For Advanced Gastro-Oesophageal Cancer

From 2023 ASCO GI Cancers Symposium:
Phase III trial findings point to a significant overall survival improvement with regorafenib versus placebo for treatment-refractory locally advanced or metastatic gastric or oesophagogastric junction cancer

Haematological Malignancies;  Leukaemia;  Lymphomas

Zanubrutinib ‘Superior’ To Ibrutinib For Relapsed, Refractory CLL and SLL

From 64th ASH Annual Meeting & Exposition:
The phase III ALPINE trial demonstrates a progression-free survival advantage for zanubrutinib versus ibrutinib among patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma

Central Nervous System Malignancies;  Lymphomas

High-Dose Chemotherapy Outperforms Immunochemotherapy for Primary CNS Lymphoma

From 64th ASH Annual Meeting & Exposition:
Individuals with primary central nervous system lymphoma have better survival when given consolidation high-dose chemotherapy and autologous stem cell transplantation rather than non-myeloablative chemoimmunotherapy

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.